$1250 | Single User
$1800 | Site License
$2500 | Global License

Liver Cirrhosis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 04 Feb 2019 | 270536 | In Stock
Related Topics: Cirrhosis , Clinical Trials , Drug

Introduction

GervanoRA's Market Estimation report "Liver Cirrhosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)" analyzed the current and upcoming opportunities in the Liver Cirrhosis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Liver Cirrhosis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Liver Cirrhosis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Liver Cirrhosis Drug Class, Route of Administration and Distribution Channel.

Report primarily focuses on the patent analysis of the key pipeline drugs to provide a brief understanding about the market opportunities in the Liver Cirrhosis competitive environment. We have also prognosticated the Liver Cirrhosis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Epidemiology and Epidemiology forecast 2018-2023

Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

Estimated Pipeline Drug Approval Timelines

Clinical Trials Summary

Current and Future Competitive Landscape

Key Company Profiles with SWOT Analysis

Emerging Company Profiles with Opportunity Assessments

Pipeline Drug Descriptions along with Development milestones (Past and Future)

Table of Contents
for Liver Cirrhosis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

  • TABLE OF CONTENTS

    1 INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS

    1.4. ABOUT US: GERVANORA DATA SERVICES

    2 EXECUTIVE SUMMARY

    2.1. MARKET SNAPSHOT, 2018-2028

    2.2. KEY PIPELINE EVENTS (REGULATORY APPROVALS) 2020-2035

    2.3. KEY MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. OPPORTUNITIES

    3 DISEASE OVERVIEW

    3.1. DISEASE DEFINITION & SYMPTOMS

    3.2. DISEASE CAUSE AND CLASSIFICATION

    3.3. DISEASE DIAGNOSIS

    3.4. TREATMENT ALGORITHM AND GUIDELINES

    3.5. EPIDEMIOLOGY AND DISEASE BURDEN

    3.6. EPIDEMIOLOGY FORECAST

    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION

    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    4 MARKET DYNAMICS

    4.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

    5 PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT

    5.1.1. PHASE 3 MOLECULES

    5.1.2. PHASE 2 MOLECULES

    5.1.3. PHASE 1 MOLECULES

    5.1.4. PRECLINICAL MOLECULES

    5.1.5. EARLY R&D MOLECULES

    5.2. PIPELINE ANALYSIS BY INDICATION

    5.3. PIPELINE ANALYSIS BY GEOGRAPHY

    5.3.1. UNMET NEEDS AND OPPORTUNITIES

    5.4. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    5.4.1. UNMET NEEDS AND OPPORTUNITIES

    5.5. PIPELINE ANALYSIS BY DRUG CLASS

    5.5.1. UNMET NEEDS AND OPPORTUNITIES

    5.6. PIPELINE ANALYSIS BY MECHANISM OF ACTION

    5.6.1. UNMET NEEDS AND OPPORTUNITIES

    5.7. ESTIMATED APPROVAL TIMELINES

    5.7.1. METHODOLOGY

    5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    6 LIVER CIRRHOSIS CLINICAL TRIALS SUMMARY

    6.1. LIVER CIRRHOSIS PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS

    6.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS

    6.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS

    6.2. ONGOING CLINICAL TRIALS SUMMARY

    7 GLOBAL LIVER DISEASES MARKET BY DRUG CLASS

    7.1. DIURETICS

    7.2. ANTIVIRAL DRUGS

    7.3. BETA-BLOCKERS (B-BLOCKERS)

    7.4. HORMONES

    7.5. ANTIBIOTICS

    7.6. AMMONIA REDUCER

    8 LIVER CIRRHOSIS MARKET, BY ROUTE OF ADMINISTRATION

    8.1. ORAL

    8.2. INJECTABLES

    9 LIVER CIRRHOSIS MARKET, BY DISTRIBUTION CHANNEL

    9.1. HOSPITAL PHARMACIES

    9.2. RETAIL PHARMACIES

    9.3. ONLINE PHARMACIES

    10 GLOBAL LIVER CIRRHOSIS THERAPEUTIC MARKET BY GEOGRAPHY

    9.1 US

    9.2 UK

    9.3 GERMANY

    9.4 FRANCE

    9.5 ITALY

    9.6 SPAIN

    9.7 JAPAN

    9.8 CHINA

    9.9 INDIA

    9.1 BRAZIL

    9.11 RUSSIA

    9.12 ROW

    11 CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    11.1. ESTABLISHED COMPANIES

    11.1.1. ESTABLISHED COMPANIES AND SWOT

    11.2. EMERGING COMPANIES

    11.2.1. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS

    12 ABBREVIATIONS

List Of Tables
in Liver Cirrhosis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

LIST OF TABLES

TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS

TABLE 02: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU

TABLE 03: MAJOR ACQUISITIONS AND MERGERS IN LIVER DISEASES THERAPEUTIC AREA

TABLE 04: MAJOR COLLABORATIVE AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA

TABLE 05: MAJOR LICENSING AGREEMENTS IN LIVER DISEASES THERAPEUTIC AREA

TABLE 06: MAJOR PARTNERSHIPS IN LIVER DISEASES THERAPEUTIC AREA

TABLE 07: PHASE 3 MOLECULES IN THE LIVER DRUG PIPELINE

TABLE 08: PHASE 2 MOLECULES IN THE LIVER DISEASES DRUG PIPELINE

TABLE 09: PHASE 1 MOLECULES IN THE LIVER DRUG PIPELINE

TABLE 10: PRECLINICAL MOLECULES IN THE LIVER DISEASE DRUG PIPELINE

TABLE 11: EARLY R&D MOLECULES IN THE LIVER DISEASE DRUG PIPELINE

TABLE 12: LIVER CIRRHOSIS PIPELINE MOLECULES, BY INDICATION TYPE

TABLE 13: LIVER DISEASES DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION

TABLE 14: LIVER DISEASES DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION

TABLE 15: LIVER DISEASES DRUG PIPELINE MOLECULES BY INJECTABLE AS ROUTE OF ADMINISTRATION

TABLE 16: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO FXR DRUG CLASS

TABLE 17: LIVER DISEASES DRUG PIPELINE MOLECULES BELONGING TO TLR INHIBITORS DRUG CLASS

TABLE 18: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES

TABLE 19: LIVER CIRRHOSIS PIPELINE DRUGS CLINICAL TRIALS SUMMARY

TABLE 20: CENICRIVIROC (CVC) AURORA STUDY DESIGN

TABLE 21: SELADELPAR ENHANCE STUDY DESIGN

TABLE 22: ELAFIBRANOR RESOLVE-IT STUDY DESIGN

TABLE 23: OCA REGENERATE STUDY DESIGN

TABLE 24: OCA REVERSE STUDY DESIGN

TABLE 25: ARAMCHOL ARREST STUDY DESIGN

TABLE 26: MGL-3196 PHASE 2 STUDY DESIGN

TABLE 27: GLOBAL LIVER CIRRHOSIS MARKET BY DRUG CLASS, MARKET SIZE (2017) AND FORECAST (2018-2028)

TABLE 28: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 29: GLOBAL DIURETICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 30: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 31: GLOBAL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 32: GLOBAL BETA-BLOCKERS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)

TABLE 33: GLOBAL HORMONES MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017) AND FORECAST (2018-2028)

TABLE 34: GLOBAL ANTIBIOTICS MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 35: GLOBAL AMMONIA REDUCER MARKET FOR LIVER CIRRHOSIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 36: GLOBAL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 37: GLOBAL LIVER CIRRHOSIS MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 38: GLOBAL LIVER CIRRHOSIS MARKET FOR INJECTABLE DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 39: GLOBAL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 40: GLOBAL LIVER CIRRHOSIS MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 41: GLOBAL LIVER CIRRHOSIS MARKET FOR RETAIL PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 42: GLOBAL LIVER CIRRHOSIS MARKET FOR ONLINE PHARMACIES BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 43: GLOBAL LIVER CIRRHOSIS MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 44: US LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 45: US DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 46: US ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 47: US LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 48: US LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 49: UK LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 50: UK DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 51: UK ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 52: UK LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 53: UK LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 54: GERMANY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 55: GERMANY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 56: GERMANY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 57: GERMANY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 58: GERMANY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 59: FRANCE LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 60: FRANCE DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 61: FRANCE ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 62: FRANCE LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 63: FRANCE LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 64: ITALY LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 65: ITALY DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 66: ITALY ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 67: ITALY LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 68: ITALY LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 69: SPAIN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 70: SPAIN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 71: SPAIN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 72: SPAIN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 73: SPAIN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 74: JAPAN LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 75: JAPAN DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 76: JAPAN ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 77: JAPAN LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 78: JAPAN LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 79: CHINA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 80: CHINA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 81: CHINA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 82: CHINA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 83: CHINA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 84: INDIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 85: INDIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 86: INDIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 87: INDIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 88: INDIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 89: BRAZIL LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 90: BRAZIL DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 91: BRAZIL ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 92: BRAZIL LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 93: BRAZIL LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 94: RUSSIA LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 95: RUSSIA DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 96: RUSSIA ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 97: RUSSIA LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 98: RUSSIA LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 99: ROW LIVER CIRRHOSIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 100: ROW DIURETICS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 101: ROW ANTIVIRAL DRUGS MARKET FOR LIVER CIRRHOSIS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 102: ROW LIVER CIRRHOSIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 103: ROW LIVER CIRRHOSIS MARKET FOR DISTRIBUTION CHANNEL BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 104: MAJOR PRODUCTS: MERCK

TABLE 105: MERCK'S NEW MOLECULAR ENTITIES UNDER REVIEW

TABLE 106: MERCK'S PHASE 3 DRUG CANDIDATES

TABLE 107: MERCK'S PHASE 2 DRUG CANDIDATES

TABLE 108: APPROVALS AND LAUNCHES BY MERCK

TABLE 109: R&D ACTIVITIES OF MERCK

TABLE 110: CONFERENCES/EVENTS ATTENDED BY MERCK

TABLE 111: RECENT DEVELOPMENTS MADE BY MERCK

TABLE 112: MAJOR PRODUCTS: GSK

TABLE 113: GSK'S KEY PIPELINE DRUG CANDIDATES

TABLE 114: APPROVALS AND LAUNCHES BY GSK

TABLE 115: R&D ACTIVITIES OF GSK

TABLE 116: CONFERENCES/EVENTS ATTENDED BY GSK

TABLE 117: RECENT DEVELOPMENTS MADE BY GSK

TABLE 118: EMERGING OPPORTUNITIES IN LIVER DISEASES THERAPEUTIC AREA

TABLE 119: TERNS PHARMACEUTICALS PIPELINE MOLECULES

TABLE 120: R&D MILESTONES ACHIEVED, TERNS PHARMACEUTICALS

TABLE 121: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA

TABLE 122: R&D ACTIVITIES OF CAN-FITE BIOPHARMA

TABLE 123: PRESENTATIONS/CONFERENCES/EVENTS BY CAN-FITE BIOPHARMA

TABLE 124: PUBLICATIONS OF CAN-FITE BIOPHARMA

TABLE 125: PARTNERSHIPS BY CAN-FITE BIOPHARMA

TABLE 126: RECENT DEVELOPMENTS OF CAN-FITE BIOPHARMA

TABLE 127: PIPELINE PRODUCTS OF EA PHARMA

TABLE 128: PATENTS OF EA PHARMA

TABLE 129: R&D ACTIVITIES OF EA PHARMA

TABLE 130: PRESENTATIONS AND PUBLICATIONS BY EA PHARMA

TABLE 131: MILESTONES ACHIEVED BY EA PHARMA

TABLE 132: RECENT DEVELOPMENTS OF EA PHARMA

TABLE 133: PIPELINE PRODUCTS OF CAN-FITE BIOPHARMA

TABLE 134: R&D ACTIVITIES OF BIOVIE

TABLE 135: RECENT DEVELOPMENTS OF BIOVIE

TABLE 136: RECENT ACTIVITIES OF CIRIUS THERAPEUTICS

TABLE 137: PUBLICATIONS ON LIVER BY CIRIUS THERAPEUTICS

TABLE 138: PIPELINE PRODUCTS OF GENFIT

TABLE 139: U.S PATENTS OF GENFIT

TABLE 140: R&D ACTIVITIES OF GENFIT

TABLE 141: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY GENFIT

TABLE 142: PUBLICATIONS OF GENFIT

TABLE 143: PIPELINE PRODUCTS OF CYMABAY THERAPEUTICS

TABLE 144: U.S PATENTS OF CYMABAY THERAPEUTICS

TABLE 145: R&D ACTIVITIES OF CYMABAY THERAPEUTICS

TABLE 146: ANTICIPATED MILESTONES OF CYMABAY THERAPEUTICS

TABLE 147: RECENT DEVELOPMENTS BY CYMABAY THERAPEUTICS

TABLE 148: PRESENTATIONS/CONFERENCES/EVENTS BY CYMABAY THERAPEUTICS

TABLE 149: R&D ACTIVITIES OF GALMED PHARMACEUTICALS LTD

TABLE 150: PRESENTATIONS/CONFERENCES/EVENTS OF GALMED PHARMACEUTICALS LTD

TABLE 151: PUBLICATIONS BY GALMED PHARMACEUTICALS LTD

TABLE 152: RECENT DEVELOPMENTS OF GALMED PHARMACEUTICALS LTD

TABLE 153: PIPELINE PRODUCTS OF ENYO PHARMA SA

TABLE 154: R&D ACTIVITIES OF ENYO PHARMA SA

TABLE 155: PRESENTATIONS/CONFERENCES/EVENTS BY ENYO PHARMA SA

TABLE 156: RECENT DEVELOPMENTS OF ENYO PHARMA SA

TABLE 157: PIPELINE PRODUCTS OF POXEL SA

TABLE 158: ANTICIPATED MILESTONES OF POXEL SA

TABLE 159: R&D ACTIVITIES OF POXEL SA

TABLE 160: PRESENTATIONS/CONFERENCES/EVENTS ATTENDED BY POXEL SA

TABLE 161: POSTER PRESENTATIONS BY POXEL SA

TABLE 162: RECENT DEVELOPMENTS OF POXEL SA

List Of Figures, Charts and Diagrams
in Liver Cirrhosis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028)

LIST OF FIGURES

FIGURE 1: GLOBAL LIVER CIRRHOSIS MARKET 2017-2028: MARKET SNAPSHOT

FIGURE 2: GLOBAL LIVER CIRRHOSIS MARKET BY GEOGRAPHY 2017 V/S 2028

FIGURE 3: LIVER CIRRHOSIS MARKET BY ROA, 2017

FIGURE 4: LIVER CIRRHOSIS MARKET BY DISTRIBUTION CHANNEL, 2017

FIGURE 5: KEY PIPELINE EVENTS, 2020-2035

FIGURE 6: CIRRHOSIS OF THE LIVER

FIGURE 7: PATHOGENESIS AND PATHOPHYSIOLOGY OF CIRRHOSIS OF THE LIVER

FIGURE 8: ETILOGY AND COMPLICATIONS OF CIRRHOSIS OF THE LIVER

FIGURE 9: CLASSIFICATION OF CIRRHOSIS OF THE LIVER

FIGURE 10: LIVER CIRRHOSIS EPIDEMIOLOGY (2017), FORECAST (2018-2023), US AND EU

FIGURE 11: OVERALL DEALS ACTIVITY IN LIVER DISEASES THERAPEUTIC AREA

FIGURE 12: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE

FIGURE 13: DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT

FIGURE 14: LIVER CIRRHOSIS PIPELINE SPLIT BY INDICATION TYPE

FIGURE 15: DRUG PIPELINE ANALYSIS BY GEOGRAPHY

FIGURE 16: LIVER DISEASE DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 17: DRUG CLASS CLASSIFICATION OF LIVER DISEASES DRUG PIPELINE

FIGURE 18: ONGOING CLINICAL TRIAL SUMMARY

FIGURE 19: ANTIVIRAL DRUGS HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018

FIGURE 20: ORAL ROUTE OF ADMINISTRATION IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018

FIGURE 21: RETAIL PHARMACIES ARE EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018

FIGURE 22: US IS EXPECTED TO HOLD MAXIMUM SHARE IN THE LIVER CIRRHOSIS MARKET, 2018

FIGURE 23: FINANCIAL INFORMATION OF MERCK, 2018

FIGURE 24: SWOT ANALYSIS OF MERCK

FIGURE 25: FINANCIAL INFORMATION, GSK

FIGURE 26: SWOT ANALYSIS OF GSK

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270536 | GERPHME227

Number of Pages

207

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Liver Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Global Liver Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical...
14 Sep 2016 by Global Data USD $4,000 More Info
One Way Liver, S.L. - Medical Equipment - Deals and Alliances Profile
SummaryONE WAY LIVER, S.L (OWL), formerly One Way Liver Genomics, S.L., is a biotechnology company t...
22 Aug 2016 by Global Data USD $250 More Info
One Way Liver, S.L. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryONE WAY LIVER, S.L (OWL), formerly One Way Liver Genomics, S.L., is a biotechnology company t...
10 May 2016 by Global Data USD $250 More Info
One Way Liver, S.L. - Medical Equipment - Deals and Alliances Profile
SummaryONE WAY LIVER, S.L (OWL), formerly One Way Liver Genomics, S.L., is a biotechnology company t...
15 Apr 2016 by Global Data USD $250 More Info
One Way Liver, S.L. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryONE WAY LIVER, S.L (OWL), formerly One Way Liver Genomics, S.L., is a biotechnology company t...
15 Mar 2016 by Global Data USD $250 More Info
One Way Liver, S.L. - Medical Equipment - Deals and Alliances Profile
SummaryONE WAY LIVER, S.L (OWL), formerly One Way Liver Genomics, S.L., is a biotechnology company t...
25 Feb 2016 by Global Data USD $250 More Info
Liver Diseases Global Clinical Trials Review, H2, 2015
Liver Diseases Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Li...
16 Dec 2015 by Global Data USD $2,500 More Info
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015SummaryGlobalData's...
16 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Liver Cirrhosis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018-2028) | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...